The startup produces medical isotopes and radiopharmaceuticals for enhanced disease imaging and targeted cell destruction. By supplying a diverse range of medical-grade isotopes, it supports researchers in improving diagnostic accuracy and treatment efficacy in oncology and infectious diseases.
Funding
$100.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
The medical community faces shortages of critical medical-grade isotopes, which are essential for accurate disease imaging and effective targeted cell destruction in oncology and infectious diseases. Dependence on foreign sources and limited domestic production capacity contribute to supply chain vulnerabilities.
Solution
AZIsotopes addresses the shortage of medical isotopes by specializing in the development and production of a broad spectrum of isotopes. The company's radiopharmaceutical production and research complex houses a 70-MeV proton cyclotron and hot cells for chemical processing, enabling high-power irradiation of targets to increase product yields. AZIsotopes focuses on isotopes in high demand, such as Strontium-82, Germanium-68, Iodine-123, and Actinium-225, to improve diagnostic accuracy and treatment efficacy. The facility's proximity to an active airfield facilitates rapid transport of short half-life radioactive products.
Target Audience
AZIsotopes serves nuclear medicine facilities, hospitals, radiopharmaceutical companies, and research institutions requiring medical-grade isotopes for diagnostic imaging, therapeutic treatments, and research applications.
Features
- Production of Strontium-82 (Sr-82) for Rubidium-82 (Rb-82) generators used in myocardial perfusion imaging via PET.
- Production of Germanium-68 (Ge-68) for PET scanner calibration and Gallium-68 (Ga-68) generators used in cancer treatment.
- Production of Iodine-123 (I-123) for thyroid imaging and activity determination with lower radiation dose to the patient compared to I-131.
- Production of Actinium-225 (Ac-225) for targeted alpha therapy treatment of cancers, including prostate, brain, and neuroendocrine cancers.
- Capability to produce Actinium 225 with 227 Spike, offering a longer life than Ac-225.
- Manufacturing of Cobalt-57 (Co-57) for calibration standards of radiometric equipment and medical Gamma Cameras.
- Use of a 70-MeV proton cyclotron with variable proton energies to access a broad set of target nuclear excitation functions.
- Six irradiation cells shielded by 3-meter-thick walls and ceilings for radiological protection.
- Hot cells equipped for automated or semi-automated radiochemical processing using ion exchange chromatography for separation and purification.